These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 32524297

  • 1. Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial.
    Li B, Alvir J, Stewart M.
    Cardiol Ther; 2020 Dec; 9(2):535-540. PubMed ID: 32524297
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
    Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, Patterson TA, Riley S, Schwartz JH, Sultan MB, Witteles R.
    Eur J Heart Fail; 2021 Feb; 23(2):277-285. PubMed ID: 33070419
    [Abstract] [Full Text] [Related]

  • 3. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
    Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, Ebede B, Gundapaneni B, Li B, Sultan MB, Shah SJ.
    Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB, Januzzi JL, O'Neill BJ, Gundapaneni B, Patterson TA, Sultan MB, López-Sendón J.
    Am J Cardiol; 2021 Jun 01; 148():146-150. PubMed ID: 33667442
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
    Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS.
    JACC Heart Fail; 2021 Feb 01; 9(2):115-123. PubMed ID: 33309574
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effect of long-term tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy (ATTR-CM): A plain language summary.
    Grogan M, Davis MK, Crespo Leiro MG, Sultan MB, Gundapaneni B, Angeli FS, Hanna M.
    Future Cardiol; 2024 Feb 01; 20(11-12):595-603. PubMed ID: 39258729
    [Abstract] [Full Text] [Related]

  • 13. Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary.
    Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Sultan MB, Maurer MS.
    Future Cardiol; 2022 Mar 01; 18(3):165-172. PubMed ID: 34779246
    [Abstract] [Full Text] [Related]

  • 14. Effect of Tafamidis on Renal Function in Patients With Transthyretin Amyloid Cardiomyopathy in ATTR-ACT.
    Sperry BW, Sultan MB, Gundapaneni B, Tai SS, Witteles RM.
    JACC CardioOncol; 2024 Apr 01; 6(2):300-306. PubMed ID: 38774010
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis.
    Vong C, Boucher M, Riley S, Harnisch LO.
    Am J Cardiovasc Drugs; 2021 Sep 01; 21(5):535-543. PubMed ID: 33770392
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
    Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators.
    Circ Heart Fail; 2017 Jun 01; 10(6):. PubMed ID: 28611125
    [Abstract] [Full Text] [Related]

  • 20. Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy.
    Grogan M, Davis MK, Crespo-Leiro MG, Sultan MB, Gundapaneni B, Stedile Angeli F, Hanna M.
    Eur J Heart Fail; 2024 Mar 01; 26(3):612-615. PubMed ID: 38439606
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.